Jerrold B. Grossman Sells 10,000 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) Stock

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) Director Jerrold B. Grossman sold 10,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the transaction, the director now owns 478,194 shares of the company's stock, valued at $10,190,314.14. The trade was a 2.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

ADMA Biologics Stock Up 4.8%

Shares of ADMA traded up $1.01 during trading hours on Wednesday, hitting $21.87. The stock had a trading volume of 4,139,333 shares, compared to its average volume of 3,660,966. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm has a 50 day simple moving average of $20.74 and a 200-day simple moving average of $18.86. The firm has a market capitalization of $5.22 billion, a P/E ratio of 78.11 and a beta of 0.47. ADMA Biologics, Inc. has a 1-year low of $10.21 and a 1-year high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. During the same period last year, the business posted $0.08 EPS. The company's revenue was up 40.2% on a year-over-year basis. Sell-side analysts predict that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

Analysts Set New Price Targets

ADMA has been the topic of a number of recent analyst reports. Raymond James boosted their price objective on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th. Finally, Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $24.25.

Hedge Funds Weigh In On ADMA Biologics

A number of hedge funds and other institutional investors have recently modified their holdings of ADMA. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in ADMA Biologics by 1.3% during the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock worth $865,000 after purchasing an additional 645 shares during the last quarter. Cetera Investment Advisers lifted its holdings in ADMA Biologics by 1.3% during the first quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company's stock valued at $1,002,000 after purchasing an additional 670 shares in the last quarter. Oregon Public Employees Retirement Fund grew its holdings in ADMA Biologics by 1.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock valued at $954,000 after buying an additional 700 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in ADMA Biologics by 1.1% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company's stock valued at $1,323,000 after acquiring an additional 711 shares during the last quarter. Finally, Summit Investment Advisors Inc. lifted its holdings in ADMA Biologics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock worth $404,000 after buying an additional 746 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.